Changes of Cerebral Glucose Metabolism After Escitalpram Treatment in Panic Disorder
Information source: Samsung Medical Center
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Panic Disorder
Intervention: escitalopram (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Samsung Medical Center Official(s) and/or principal investigator(s):
Bum-Hee Yu, MD & PhD, Principal Investigator, Affiliation: Samsung Medical Center, Sungkyunkwan University School of Medicine
Summary
The aim of this study is to test the following hypotheses using 18F-FDG positron emission
tomography (PET): 1) Patients with panic disorder will show greater activity of the fear
network than healthy comparison subjects. 2) Patients with panic disorder will show reduced
activity of the fear network after 12-weeks of treatment with escitalopram. 3) The changes of
fear network after the treatment will help to explain anti-panic mechanism of escitalopram in
panic disorder patients.
Clinical Details
Official title: Neuroimaging Study of Panic Disorder According to Escitalopram Treatment
Study design: Longitudinal, Case Control, Prospective Study
Detailed description:
Panic disorder (PD) is one of the most prevalent psychiatric disorders and recently abnormal
fear network is known to be implicated in the pathophysiology of panic disorder. The fear
network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (PAG),
locus coeruleus, parahippocampal gyrus, dorsolateral prefrontal cortex, and thalamus.
Escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic
disorder, but there is little information on how escitalopram affects the fear network. The
aim of this study is to test the following hypotheses using 18F-FDG positron emission
tomography (PET): 1) Patients with panic disorder will show greater activity of the fear
network than healthy comparison subjects. 2) Patients with panic disorder will show reduced
activity of the fear network after 12-weeks of treatment with escitalopram. 3) The changes of
fear network after the treatment will help to explain anti-panic mechanism of escitalopram in
panic disorder patients.
Eligibility
Minimum age: 20 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- panic disorder patients who have no history of taking anti-panic medications
- panic disorder patients who are aged from 20 to 60 years
Exclusion Criteria:
- Subjects who have current or a history of any major medical or psychiatric illnesses
Locations and Contacts
Samsung Medical Ceter, Seoul 135-710, Korea, Republic of; Recruiting
Tae Geun Kim, Phone: 822-3410-2975, Email: tggo.kim@samsung.com
Bum-Hee Yu, MD & PhD, Principal Investigator
Additional Information
Starting date: April 2007
Ending date: June 2008
Last updated: August 13, 2007
|
